• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Need for symptomatic management in advanced multiple sclerosis.

作者信息

Rønning O M, Tornes K D

机构信息

Department of Neurology, Akershus University Hospital, Lørenskog, Norway.

Institute of Clinical Medicine, University of Oslo, Oslo, Norway.

出版信息

Acta Neurol Scand. 2017 May;135(5):529-532. doi: 10.1111/ane.12631. Epub 2016 Jun 29.

DOI:10.1111/ane.12631
PMID:27357364
Abstract

OBJECTIVE

A majority of patients with advanced multiple sclerosis (MS) need symptomatic treatment. Many MS-related symptoms may not be recognized and thus are not treated. We conducted a study to estimate the prevalence of inadequate symptomatic treatment of patients with advanced MS.

METHODS

Patients with advanced MS admitted to a specialist MS rehabilitation clinic were included in this study. Severity was assessed using the Expanded Disability Status Scale (EDSS). The information we collected included age of onset, initial course, time to sustained disability, pharmacological treatment, degree of spasticity, pain and bladder dysfunction, and unmet needs of symptomatic treatment.

RESULTS

In total, we assessed demographic and clinical characteristics in 129 patients with a mean age of 56 years and a median EDSS of 7.5. The proportion with inadequate symptom treatment was regarding spasticity 46%, pain 28%, and bladder dysfunction 23%.

DISCUSSION

This study showed that a large proportion of patients with advanced MS had lack of symptomatic treatment. These patients probably underuse neurological specialist services. Better symptomatic treatment could contribute to improving quality of life of people with MS.

摘要

相似文献

1
Need for symptomatic management in advanced multiple sclerosis.
Acta Neurol Scand. 2017 May;135(5):529-532. doi: 10.1111/ane.12631. Epub 2016 Jun 29.
2
Clinical case reviews and poster sessions in multiple sclerosis spasticity: main outcomes and highlights.多发性硬化症痉挛的临床病例回顾与海报展示:主要成果与亮点
Eur Neurol. 2014;72 Suppl 1:15-9. doi: 10.1159/000367619. Epub 2014 Sep 26.
3
Symptomatic treatment in multiple sclerosis-interim analysis of a nationwide registry.多发性硬化症的对症治疗——一项全国性登记研究的中期分析
Acta Neurol Scand. 2017 Apr;135(4):394-399. doi: 10.1111/ane.12612. Epub 2016 Jun 9.
4
Symptomatic medication use in multiple sclerosis.多发性硬化症的对症药物治疗
Mult Scler. 2003 Oct;9(5):458-60. doi: 10.1191/1352458503ms957oa.
5
Advances in the management of multiple sclerosis symptoms: pathophysiology and assessment of spasticity in multiple sclerosis.多发性硬化症状管理的进展:多发性硬化中痉挛的病理生理学与评估
Neurodegener Dis Manag. 2015;5(6 Suppl):15-7. doi: 10.2217/nmt.15.56.
6
Symptomatology and symptomatic treatment in multiple sclerosis: Results from a nationwide MS registry.多发性硬化症的症状学和症状治疗:来自全国多发性硬化症登记处的结果。
Mult Scler. 2019 Oct;25(12):1641-1652. doi: 10.1177/1352458518799580. Epub 2018 Sep 19.
7
Long-Term Data of Efficacy, Safety, and Tolerability in a Real-Life Setting of THC/CBD Oromucosal Spray-Treated Multiple Sclerosis Patients.四氢大麻酚/大麻二酚口腔黏膜喷雾剂治疗多发性硬化症患者的现实环境中的长期疗效、安全性和耐受性数据。
J Clin Pharmacol. 2016 Jul;56(7):845-51. doi: 10.1002/jcph.670. Epub 2015 Dec 30.
8
Spasticity in multiple sclerosis: results of a patient survey.多发性硬化症中的痉挛:一项患者调查结果
Int J Neurosci. 2013 Jun;123(6):400-8. doi: 10.3109/00207454.2012.762364. Epub 2013 Feb 18.
9
[Epidemiology and clinical assessment of spasticity in multiple sclerosis].[多发性硬化症中痉挛状态的流行病学与临床评估]
Rev Neurol (Paris). 2012 Apr;168 Suppl 3:S45-50. doi: 10.1016/S0035-3787(12)70046-2.
10
Country break-out session highlights.各国分组会议要点
Neurodegener Dis Manag. 2015;5(6 Suppl):31-7. doi: 10.2217/nmt.15.58.

引用本文的文献

1
Advanced multiple sclerosis: an exploratory study on a neglected patient population.进展型多发性硬化症:对一个被忽视患者群体的探索性研究。
J Neurol. 2025 Aug 3;272(8):553. doi: 10.1007/s00415-025-13296-6.
2
Mood Associated With Health- and Social Care-Related Quality of Life in Patients With Advanced Multiple Sclerosis.晚期多发性硬化症患者的情绪与健康及社会护理相关生活质量的关系
Int J MS Care. 2024 Aug 1;26(Q3):199-206. doi: 10.7224/1537-2073.2023-060. eCollection 2024 May.
3
Lack of Attention to the Administration of Fampridine as a Symptomatic Drug in Iranian Multiple Sclerosis Patients.
伊朗多发性硬化症患者中作为对症药物的氨吡啶使用情况未受到关注。
Iran J Public Health. 2021 Jul;50(7):1513-1514. doi: 10.18502/ijph.v50i7.6654.
4
Inequalities in pharmacologic treatment of spasticity in Sweden - health economic consequences of closing the treatment gap.瑞典痉挛药物治疗的不平等——缩小治疗差距的健康经济后果
Health Econ Rev. 2020 Feb 7;10(1):4. doi: 10.1186/s13561-020-0261-7.